Contact PR

To use this feature, join Babbler easily !

arrow_back

Babbler allows PR people and reporters to collaborate a better way.

By joining Babbler you will be able to access hundreds of newsrooms and PR contacts from your industrie(s) and also share with them your upcoming needs.

Their newsrooms are already on Babbler

You're 1 click away from signing up

Previous

Nice to see you again !

Press release

SANOFI ON BEHALF OF LEXICON PHARMACEUTICALS
timer minutes reading time minute reading time

Copy link
Lexicon Pharmaceuticals announces positive 52-week results from sotagliflozin inTandem2 study presented at ADA 2018 and published in Diabetes Care
sanofi-on-behalf-of-lexicon-pharmaceuticals-1

Click to get original image size

Addressing the need for additional therapeutic options alongside insulin in type 1 diabetes

June 23, 2018

Background:

Insulin is the cornerstone of therapy for people with type 1 diabetes. But insulin-related challenges—like hypoglycemia, weight gain, and patient burden—can limit the majority of patients with T1D from reaching their target glucose levels.

  • Health & Medicine
  • Medicine
inscrit avec succès

Congratulations, you're registered on Babbler!

Discover now all the news waiting for you on Babbler: visit your newsfeed.!

Your topics have been selected, you can change it by clicking here

  • Health & Medicine
  • Medicine